Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
Vaxart is urging shareholders to vote for its six director nominees on the WHITE proxy card ahead of the July 16 Annual Meeting to defend against a dissident campaign led by Daniel Houle. The company emphasizes the incumbent board's biotech expertise and its role in securing BARDA funding and advancing a 5,100-participant Phase 2b COVID-19 trial, arguing the dissidents lack necessary experience.
Key figures
- Annual meeting date
- July 16, 2026
- Sentinel cohort size
- 400
- Capital raised 2025 usd
- 40000000
- Phase 2b main cohort size
- 5100
- Share purchase agreement usd
- 25000000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.